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Abstract 
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran or rivaroxaban are alterna-
tives to vitamin K antagonists (VKAs) for prevention of stroke and systemic embolism in patients with atrial fibrillation 
(AF) and atrial flutter (AFL). Incidences of risk factors for left atrium (LA) and left atrial appendage (LAA) thrombus 
formation, such as dense spontaneous echo contrast (SEC), low LAA velocity (LAAV) <20 cm/s under treatment with 
dabigatran and rivaroxaban in comparison with VKAs are unknown.
Methods: We studied 306 patients with AF (94 %) and AFL (6 %) undergoing transesophageal echocardiography. 
Patients received VKAs (n = 138), dabigatran (n = 68), or rivaroxaban (n = 100) for at least 3 weeks prior to investiga-
tion. Time in therapeutic range was 67 % for VKA. Mean CHADS2 score and CHA2DS2-VASc score were 1.3 and 2.5, 
respectively. Left atrial abnormality was defined as either dense SEC, low LAAV <20 cm/s, or thrombus.
Results: Any LA abnormality occurred in 9, 3, and 5 % of patients receiving VKA, dabigatran, and rivaroxaban, respec-
tively. The most frequent abnormality was LAA thrombus (VKA: 4 %, dabigatran: 0 %, rivaroxaban: 2 %) and low LAAV 
of less than 20 cm/s (VKA: 4 %, dabigatran: 1 %, rivaroxaban: 1 %), followed by dense SEC (VKA: 2 %, dabigatran: 1 %, 
rivaroxaban: 2 %). Results of uni- and multivariate analyses revealed a numerically lower but not significantly different 
frequency of any LA abnormality under dabigatran (OR 0.4, 95 % Cl 0.08 − 1.88, p = 0.25) and rivaroxaban (OR 0.65, 
95 % Cl 0.22 − 1.98, p = 0.45) compared to VKA.
Conclusion: With respect to the incidence of LA abnormalities, dabigatran and rivaroxaban are not inferior to VKA.
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© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Non-valvular atrial fibrillation (AF) is the most com-
mon sustained cardiac arrhythmia, and is associated not 
only with an increased risk of stroke and other systemic 
embolism but also increased mortality and morbidity 
[1–4]. In comparison to the general population, the risk 
of stroke is four- to fivefold higher in patients with AF 
[5]. An overview of five randomized trials has shown that 
treatment with vitamin K antagonists (VKA) reduced 
the incidence of ischemic stroke from 4.5 to 1.4  %/year 
with a relative risk reduction of 68 % in AF patients [6]. 
Pharmacokinetics and pharmacodynamics of VKA are 
influenced by many factors including nutrition leading 
to fluctuant international normalized ratio (INR) values 
and individual changes of the time in therapeutic range 
(TTR). Non-vitamin K antagonist oral anticoagulants 
(NOACs), including the direct thrombin inhibitor dabi-
gatran and the factor Xa inhibitors rivaroxaban, revealed 
a clinical benefit compared with VKA in large-scale 
phase III studies [7, 8]. Despite these benefits, there are 
many open questions in terms of specific clinical situa-
tions. Based on guidelines, for patients with AF of >48 h 
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for at least 3 weeks prior to and 4 weeks after cardiover-
sion to exclude left atrial appendage (LAA) thrombus [9, 
10]. While the efficacy of VKAs for prevention of stroke 
and systemic embolism in the cardioversion setting has 
been studied in detail [11, 12], only few studies have been 
published for NOACs [13–15]. A recently published 
study compared NOACs and VKAs in a high-risk popu-
lation, i.e., patients with a median CHA2DS2-VASc score 
of 4. The prevalence of intracardiac thrombi under VKAs 
was unexpectedly high (17.8 %) bearing risk of thrombo-
embolic events despite sufficient anticoagulation. How-
ever, it was significantly higher than under dabigatran 
(3.8 %) or rivaroxaban (4.1 %). The TTR of VKA patients 
in that study is not known. The authors concluded that 
the prevalence of intracardiac thrombi was lower under 
NOAC therapy than under VKAs [16].
Potential risk factors for thrombus formation in LA/
LAA, such as dense spontaneous echo contrast (SEC), 
and low left atrial appendage velocity (LAAV <20 cm/s) 
that are known as independent risk factors for thrombo-
embolic events have not been studied yet in detail [17–
19]. It has been demonstrated that these transesophageal 
echocardiogram (TEE) findings were stronger predictors 
of thromboembolic events than the CHADS2 score [20] 
and that the annual rate of cerebral embolism was 22 %, 
despite oral anticoagulation [21]. Although VKAs seem 
to be similarly effective than NOACs, the incidences of 
these echocardiographic LA abnormalities under treat-
ment with dabigatran, rivaroxaban, and VKAs especially 
in a mid- or low-risk population are unknown. Therefore, 
the aim of the present registry study was to identify the 
frequencies of LA abnormalities in patients treated with 




We studied 306 patients with AF and atrial flutter (AFL) 
under treatment with VKAs, dabigatran, or rivaroxaban 
referred to our department for cardioversion or cath-
eter ablation between October 2011 and December 2014. 
Exclusion criteria were atrial fibrillation due to a revers-
ible cause (e.g., hyperthyroidism, infection, transient 
perioperative AF), moderate or severe heart-valve disor-
der or prosthetic heart valve, heart transplant, need for 
aspirin at a dose of >100 mg/day or for both aspirin and a 
P2Y12 inhibitor, active liver disease, calculated creatinine 
clearance of <15 ml per minute, pregnancy, stroke within 
14  days prior to admission, and non-compliance with 
drug therapy.
All included patients with creatinine clearance ≥50 ml/
min and HAS-BLED score <3 in the dabigatran and rivar-
oxaban group received the standard dose of 150 mg BID 
and 20 mg OD, respectively. Only patients with moderate 
renal impairment (creatinine clearance 30–49  ml/min) 
or high bleeding risk (HAS-BLED score ≥3) were treated 
with reduced dose of 110  mg BID dabigatran or 15  mg 
OD rivaroxaban, as recommended in the European Soci-
ety of Cardiology (ESC) guidelines for the management 
of AF [9].
Scores
The risk of stroke or systemic embolism and hemorrhage 
was determined using the CHADS2, CHA2DS2-VASc, 
and HAS-BLED scores [9].
Transthoracic (TTE) and transesophageal 
echocardiography (TEE)
All included patients were studied by TEE and optionally 
TTE (Vivid E9, GE Healthcare, USA). Echocardiographic 
measurements were performed according to the recom-
mendations of the international standard practice guide-
lines [22, 23]. TTE was performed using a 1.5–4.6 MHz 
imaging transducer (M5S-D and M5Sc-D, GE Health-
care, USA). For TEE 3.0–8.0 MHz, a multiplane phased 
array transducer (6VT-D, GE Heathcare, USA) was used. 
Patients were sedated with midazolam and/or propofol. 
Blood pressure, heart rate, and oxygen saturation were 
continuously monitored. LA and LAA were studied in 
multiple planes. LAAs were categorized into non-banded 
and banded LAAs and four different morphology sub-
groups, as first described by Wang et  al. [24]: chicken 
wing, wind sock, cauliflower, and cactus.
LA abnormality
LA abnormality was defined as thrombus in LA/LAA, 
dense SEC, and severely reduced LAAV (≤20 cm/s) [17, 
19]. We constituted a rank order: patients with proof 
of LA/LAA thrombus were not included in the dense 
SEC- or LAAV <20 cm/s group and patients with dense 
SEC were not included in the LAAV <20 cm/s group.
Thrombus was defined as an iso- or hyperechogenic 
non-muscular and non-endocardial mass detected by 
more than one plane axis [25]. LAAV was measured by 
pulsed-wave (PW) Doppler as maximal flow velocity in 
the proximal third of the appendage. The view with the 
optimal alignment was determined by color flow imag-
ing [26]. The density of SEC was graded in 5 levels, as 
described before [26]: (0) absence of echogenicity, (+1) 
mild (minimal echogenicity located only in a part of the 
LA cavity, only transiently during the cardiac cycle, and 
only at high gain setting), (+2) mild to moderate (denser 
swirling than mild SEC but only demonstrable at high 
gain setting), (+3) moderate (dense swirling in the LAA 
und partially in the LA cavity with varying intensity), 
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(+4) dense (intense echodensity and very slow swirling in 
LAA).
To calculate the time in therapeutic range (TTR) for 
VKA group patients, the Rosendaal method was used 
[27]. The INR values of the last 6 weeks were included in 
the calculation.
Statistical analysis
The study population was described by the standard 
descriptive statistics such as frequencies, mean ± stand-
ard deviation, median with the corresponding interquar-
tile range, wherever appropriate. Inferential statistics 
were intended to be exploratory (hypotheses generating), 
not confirmatory, and are interpreted accordingly. Thus, 
p values are to be interpreted in Fisher’s sense, represent-
ing the metric weight of evidence against the respective 
null hypothesis. Neither a global significance level nor 
local levels were determined. A p value ≤0.05 was con-
sidered statistically significant.
Pair-wise differences between the anticoagulation 
groups (VKA vs. dabigatran, VKA vs. rivaroxaban, and 
dabigatran vs. rivaroxaban) were assessed respectively 
using Fisher’s exact test (for categorical variables with 
two categories), the Chi2-test (for categorical variables 
with three or more categories), and the Mann–Whitney-
U-test (for continuous variables).
In order to prevent biased results due to imbalanced 
patient’s baseline characteristics, the impact of anti-
coagulation on the risk of any LA/LAA abnormality 
was assessed by multivariate logistic regression. Model 
building was carried out by means of all-subset variable 
selection based on Akaike’s information criterion [28]. 
Coefficients from logistic regression were checked by the 
Wald-test, and odds ratios (OR) and referring 95 % confi-
dence intervals (CI) were derived. All statistical computa-
tions were carried out using R 3.1.2 (R Core Team, 2014).
Results
Baseline characteristics
Table 1 shows the clinical baseline characteristics of the 
306 patients included. The mean age was 67 with an 
interquartile range of 58–73, 60 % were male. Most of the 
patients had paroxysmal AF (56  %), followed by persis-
tent AF (36 %), permanent (1 %), and longstanding per-
sistent (<1 %). 6 % were suffering from AFL. In the VKA 
group, the TTR, defined as an INR between 2.0 to 3.0, 
was 67 %. Between the three treatment groups, some sig-
nificant differences were observed (for more details see 
Table 1).
Frequency of LA abnormalities
The groups of patients receiving VKA, dabigatran, 
and rivaroxaban medication did not yield significant 
differences with respect to frequency of LA abnormalities 
(Table  2). In summary, the frequency of LA abnormali-
ties was lowest within the dabigatran group (3  %), fol-
lowed by the rivaroxaban (5 %) and VKA group (9 %). A 
dense SEC (VKA: 1 %, dabigatran: 1 %, rivaroxaban: 2 %) 
was observed less frequently than a LA/LAA thrombus 
(VKA: 4 %, dabigatran: 0 %, rivaroxaban: 2 %), and a low 
LAAV of less than 20 cm/s (VKA: 4 %, dabigatran: 1 %, 
rivaroxaban: 1 %). The influence of VKA, dabigatran, and 
rivaroxaban on the risk of any LA abnormality was addi-
tionally analyzed by means of logistic regression mod-
els in order to prevent biased results due to imbalanced 
patient’s baseline characteristics. The results of the uni-
variate and multivariate models are given in Table 3. The 
univariate models suggest that patients with CHADS2 
score 2 and CHA2DS2-VASc score ≥4 have a signifi-
cantly higher risk of any LA abnormality than patients 
with CHADS2-score 0–1 (OR 4.40, 95 % CI 1.54–12.54, 
p  =  0.006) and CHA2DS2-VASc score 0–1 (OR 6.30, 
95 % CI 1.28–30.95, p = 0.023). The multivariate model 
includes the CHADS2 score but not the CHA2DS2-VASc 
score. It suggests that patients with CHADS2 score 2 have 
a significantly higher risk of any LA abnormality than 
patients with CHADS2 score 0–1 (OR 4.07, 95 % CI 1.42–
11.69, p  =  0.009). Neither the univariate models nor 
the multivariate model indicate a significant difference 
between dabigatran and VKA and between rivaroxaban 
and VKA.
Discussion
In the present study, we investigated the frequency of 
three echocardiographic risk factors for stroke and sys-
temic embolism in patients treated with either dabigatran 
and rivaroxaban, or with VKAs. Both NOACs showed 
numerically lower statistically non-different results in 
comparison to VKA for prevention of LA abnormalities 
in a low- to mid-risk cohort.
The current European and American guidelines rec-
ommend in AF >48  h either a sufficient therapeutic 
anticoagulation (INR >2) for at least 3  weeks or TEE 
prior to cardioversion to exclude LAA thrombus. Inter-
estingly, the guidelines do not clearly discriminate 
between oral anticoagulation with VKAs and NOACs 
[9, 10]. This recommendation is based on results of sub-
group analyses of the RE-LY and ROCKET-AF as well 
as the separate X-VeRT trial [13–15]. A recommenda-
tion regarding potential comparability of these different 
therapeutic anticoagulation regimens is based on sub-
group analyses of the RE-LY as well as the ROCKET-AF 
trial. In the RE-LY trial, a cardioversion was performed 
in 1270 patients with AF. Stroke or systemic embo-
lism at 30  days after cardioversion occurred in 0.8, 0.3, 
and 0.6  % of patients receiving dabigatran in a dose of 
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110 mg BID, 150 mg BID, and VKA, respectively [14]. In 
the ROCKET-AF trial, a cardioversion or catheter abla-
tion was carried out in 321 patients. The incidence of 
stroke or systemic embolism at 30  days after cardiover-
sion or ablation was 1.88 % in the rivaroxaban group and 
1.86 % in the VKA group [15]. However, due to a mark-
edly higher CHADS2 score, different study designs, and 
differences between TTRs, the event rates of the two 
NOACs could not be compared with each other. TTR 
in Rocket-AF was 55  % which was rather low and 64  % 
in the RE-LY study. A study published by Zylla and cow-
orkers demonstrated in a high-risk population with a 
median CHA2DS2-VASc score of 4 that the prevalence of 
intracardiac thrombi under phenprocoumon was signifi-
cantly higher (17.8  %) than in the dabigatran (3.8  %) or 
rivaroxaban group (4.1 %). Data about the TTR of VKA 
patients in which study are not available. Interestingly, 
subgroup analyses of the Rocket-AF data demonstrated 
that in rivaroxaban patients, the hazard ratio for the pri-
mary endpoint was above 1 when being compared with 
patients with a TTR of >67 %. Thus, sufficient VKA treat-
ment may, despite other hurdles such as dependence of 
INR on oral vitamin K supply, higher interaction risk, 
and need for regular INR control, be comparable with 
NOACs as long as the TTR is high enough. This is espe-
cially important in patients where thromboembolic risk 
is per se not high. In our patients, TTR was 67 %. Despite 
clear trends that favor NOACs, we did not find significant 
differences between the two groups, even not with uni-
variate or multivariate statistical models. Nevertheless, 
Table 2 Frequencies of LA abnormalities in the study population












p value for difference 
between VKA  
and Dabigatran






LA/LAA thrombus 5 (4 %) 0 (0 %) 2 (2 %) 0.173 0.515 0.702
Dense SEC 2 (1 %) 1 (1 %) 2 (2 %) 1 1 1
LAAV <20 cm/s 5 (4 %) 1 (1 %) 1 (1 %) 0.666 1 0.405
LA abnormality 12 (9 %) 2 (3 %) 5 (5 %) 0.15 0.702 0.318
Table 3 Univariate and multivariate logistic regression analyses of risk factors of any LA abnormality
CI confidence interval, LAA left atrial appendage, NSAR non-steroidal anti-rheumatic agents, OR odds ratio, VKA vitamin K antagonists
a Final model resulting from an all-subset variable selection based on Akaike’s Information Criterion; the medication group (dabigatran vs. VKA and rivaroxaban vs. 
VKA) was defined as fixed covariate, and the significant variables in column 1 were considered as possible covariates
Separate univariate models Multivariate modela
Clinical variable OR (95 % CI) p value OR (95 % CI) p value
Dabigatran vs. VKA 0.32 (0.07–1.46) 0.141 0.40 (0.08–1.88) 0.245
Rivaroxaban vs. VKA 0.55 (0.19–1.62) 0.28 0.65 (0.22–1.98) 0.453
CHADS2: 2 vs. 0–1 4.40 (1.54–12.54) 0.006 4.07 (1.42–11.69) 0.009
CHADS2: ≥3 vs. 0–1 3.80 (0.89–16.16) 0.071 3.19 (0.73–13.99) 0.124
CHA2DS2-VASC: 2 vs. 0–1 1.99 (0.38–10.55) 0.419
CHA2DS2-VASC: 3 vs. 0–1 2.03 (0.36–11.41) 0.423
CHA2DS2-VASC: ≥4 vs. 0–1 6.30 (1.28–30.95) 0.023
HAS–BLED: 2 vs. 0–1 2.57 (0.87–7.60) 0.089
HAS–BLED: ≥3 vs. 0–1 3.11 (0.70–13.80) 0.135
Non-banded LAA vs. banded LAA 0.64 (0.21–1.99) 0.443
Unknown LAA vs. banded LAA 0.00 (0.00,∞) 0.99
Beta blocker 1.64 (0.21–12.84) 0.636
Calcium blocker 0.21 (0.03–1.61) 0.133
Dronedarone 1.49 (0.32–6.89) 0.61
Statin 1.24 (0.49–3.13) 0.657
NSAR 0.77 (0.17–3.47) 0.735
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the results from the Zylla group imply that based on the 
relatively high incidence of LAA thrombi in a high-risk 
patient cohort, especially those under VKA, treatment 
may underlie a high risk of thromboembolic events dur-
ing or after electrical cardioversion.
TEE is a moderately invasive method that allows a 
detailed evaluation of the structure and function of the 
LAA. It is accurate and the gold standard for identifying 
or excluding LA/LAA thrombus [29].
The incidence of LA/LAA thrombus under treatment 
with VKA depends on the patient population studied and 
different TTR values ranging from 1.5 to 17 % [30–33]. In 
most studies, however, the incidence of LA/LAA throm-
bus was between 2 and 7 % [30, 32]. Thus, the present data 
(4 % in the VKA group) are in line with these studies. In 
the RE-LY trial, the rate of LA/LAA thrombus was 1.8, 
1.2, and 1.1 % in the dabigatran group of with 110 mg BID, 
150 mg BID, and VKA group, respectively [14]. Notably, 
we did not observe any thrombus in the dabigatran group. 
The rivaroxaban group showed a numerically slightly 
higher incidence of LA abnormalities than the dabigatran 
group, which was, however, statistically not significant.
It has been shown that patients with AF and dense SEC 
have a likelihood of stroke of 22  %/year, despite antico-
agulation [21]. Dense SEC is described with a frequency 
of 8–35 % in patients with AF, depending on the patient 
population, type and effectiveness of anticoagulation, 
and CHADS2-/CHA2DS2-VASc Score [19, 34–36]. Our 
results showed a relatively lower frequency of dense SEC 
(VKA: 1 %, dabigatran 1 %, rivaroxaban 2 %). A possible 
explanation for this difference is the high inter- and intra-
observer variability in the grading of SEC [37].
Another important indicator for thromboembolic com-
plications in patients with AF is the LAAV [34]. Reduc-
tion of the LAAV below 20  cm/s exhibited the highest 
association with stroke [38]. A LAAV less than 20 cm/s 
is found in 1 to 13  % of patients with AF [21, 34]. We 
observed an incidence of LAAV <20  cm/s that were 
numerically higher in patients receiving VKA (4 %) com-
pared to patients receiving a NOAC (1 % for dabigatran 
and rivaroxaban). This observation is in line with the 
higher CHA2DS2-VASc score in this group.
It has been demonstrated that non-banded LAA is 
associated with lower LAAV and a higher frequency of 
SEC compared with banded LAA [39]. We found no sig-
nificant association between the incidence of LA abnor-
malities and different LAA morphologies. Differences 
in the duration of AF/AFL in the different study popu-
lations could have, at least in part, contributed to these 
discrepancies.
Diastolic dysfunction is associated with a reduced 
LAA velocity, rate of SEC, and LAA thrombus in patient 
with non-valvular AF [40]. The impact of the three 
anticoagulatory drugs on LAA velocity, rate of SEC, and 
LAA thrombus in patients with non-valvular AF and 
diastolic dysfunction is unknown. Further studies are 
necessary to demonstrate the association between these 
parameters and LAA thrombus formation in patients with 
non-valvular AF under treatment with VKA and NOACs.
Several limitations of this study deserve attention. First, 
the number of investigated patients was relatively small. 
Second, there are further risk factors for stroke or sys-
temic embolism in patients with AF, e.g., aortic plaques 
[19], which have not been addressed in the current 
trial. Third, we did not study patients being treated with 
Apixaban or edoxaban. Further studies should address 
the present approach in a larger patient cohort including 
apixaban and edoxaban patients. Fourth, the CHADS2/
CHA2DS2-VASc scores are clinical classifications for 
predicting stroke in non-valvular AF and correlated with 
both dense SEC and LA/LAA thrombus [35]. The multi-
variate model in the present work also shows a close cor-
relation between the CHADS2/CHA2DS2-VASc scores 
and LA-abnormalities. It is possible that the LA abnor-
malities are associated more with both scores than the 
anticoagulation drug.
Conclusion
This is the first study addressing the incidence of LA/LAA 
thrombus formation in a predominantly low- to mid-risk 
patients cohort being treated with dabigatran or rivaroxa-
ban compared with VKAs at a TTR of >65 %. This study 
demonstrates that with respect to the incidence of echo-
cardiographic risk factors for thromboembolic events, 
both dabigatran and rivaroxaban are not inferior to VKA.
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